Ann Neale

Ann Neale is the Chief Development Officer at BioAge. Ann has over 20 years of experience in the pharmaceutical and biotech industries, with a focus on clinical development.

Ann began their career as a VP Clinical Operations at Biotie Therapies, Inc. (f/n/a Synosia Therapeutics Inc.), where they oversaw all aspects of clinical development, from study design to data analysis and interpretation. Ann then moved to XOMA, where they served as VP Clinical Operations and Data Assessment. In this role, they were responsible for the clinical development strategy and execution for all of XOMA's programs.

In 2017, Ann joined Science 37 as Senior Vice President, Clinical Operations and Patient Affairs. In this role, they were responsible for leading the company's clinical operations team and developing its patient engagement strategy. Ann left Science 37 after only six months to join Principia Biopharma as Senior Vice President Development Operations.

At Principia, Ann led the company's clinical development efforts, including defining resourcing and operations strategy, building scalable development functions, and overseeing clinical operations and trial management. Ann was with Principia for three years before the company was acquired by Sanofi in 2020. After the acquisition, Ann led the Global Clinical Development transition and integration team.

Ann is currently the Chief Development Officer at BioAge. In this role, they are responsible for leading BioAge's clinical development team and executing the company's clinical development strategy.

Ann Neale has a BS in Nursing from the University of Minnesota. Ann is currently working as a nurse at a hospital.

They work with Peng Leong - Chief Business Officer, Paul Rubin - EVP, Research & CMO, and Chris Patil - VP, Media. Ann Neale reports to Kristen Fortney, Co-Founder & CEO.